Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NPKI
1801
NPK International
NPKI
$1.21B
| $3.09M | ﹤0.01% |
744,641
+33,500
| +5% | +$123K |
|
1802
Seres Therapeutics
MCRB
$45.6M
| $3.09M | ﹤0.01% |
27,575
+630
| +2% | +$84.5K |
|
1803
Allegiant Air
ALGT
$2.34B
| $3.09M | ﹤0.01% |
45,400
-2,600
| -5% | -$190K |
|
1804
Arlo Technologies
ARLO
$1.54B
| $3.07M | ﹤0.01% |
875,100
+387,900
| +80% | +$1.6M |
|
1805
Kemper
KMPR
$1.62B
| $3.07M | ﹤0.01% |
+62,410
| New | +$3.14M |
|
1806
Air T
AIRT
$79.2M
| $3.07M | ﹤0.01% |
124,011
-7,600
| -6% | -$168K |
|
1807
Definitive Healthcare
DH
$68.2M
| $3.05M | ﹤0.01% |
277,900
+32,100
| +13% | +$413K |
|
|
PWOD
1808
DELISTED
Penns Woods Bancorp
PWOD
| $3.05M | ﹤0.01% |
114,609
-11,814
| -9% | -$296K |
|
|
MAXN
1809
DELISTED
Maxeon Solar Technologies
MAXN
| $3.04M | ﹤0.01% |
1,890
+544
| +40% | +$1.08M |
|
1810
Global Water Resources
GWRS
$247M
| $3.03M | ﹤0.01% |
228,340
-36,007
| -14% | -$454K |
|
1811
Invesco California AMT-Free Municipal Bond ETF
PWZ
$1.17B
| $3.03M | ﹤0.01% |
+125,585
| New | +$2.98M |
|
1812
Danaos Corp
DAC
$2.58B
| $3.03M | ﹤0.01% |
57,517
+42,267
| +277% | +$2.38M |
|
1813
Kodiak Sciences
KOD
$2.59B
| $3.02M | ﹤0.01% |
422,300
+92,340
| +28% | +$663K |
|
1814
SITE Centers
SITC
$155M
| $3.02M | ﹤0.01% |
283,267
-383,827
| -58% | -$3.77M |
|
|
PHLT
1815
DELISTED
Performant Healthcare Inc
PHLT
| $3.02M | ﹤0.01% |
835,963
-59,900
| -7% | -$140K |
|
1816
Marchex
MCHX
$82M
| $3M | ﹤0.01% |
1,877,464
-31,901
| -2% | -$54.3K |
|
1817
Aegon
AEG
$14B
| $3M | ﹤0.01% |
+595,596
| New | +$2.76M |
|
|
LUCK
1818
Lucky Strike Entertainment
LUCK
$949M
| $3M | ﹤0.01% |
222,500
+24,700
| +12% | +$334K |
|
1819
WisdomTree Emerging Markets High Dividend Fund
DEM
$3.97B
| $3M | ﹤0.01% |
84,100
+72,400
| +619% | +$2.51M |
|
1820
Sensient Technologies
SXT
$5.68B
| $3M | ﹤0.01% |
41,100
+26,600
| +183% | +$1.91M |
|
1821
Atea Pharmaceuticals
AVIR
$410M
| $2.98M | ﹤0.01% |
620,600
+23,200
| +4% | +$117K |
|
1822
Heritage Financial
HFWA
$1.22B
| $2.98M | ﹤0.01% |
+97,289
| New | +$3.04M |
|
1823
Mesa Laboratories
MLAB
$593M
| $2.98M | ﹤0.01% |
17,934
+9,734
| +119% | +$1.53M |
|
1824
Ultrapar
UGP
$6.55B
| $2.98M | ﹤0.01% |
1,231,800
-345,000
| -22% | -$863K |
|
1825
InfuSystem Holdings
INFU
$244M
| $2.98M | ﹤0.01% |
342,909
-23,400
| -6% | -$191K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.